Abstract Our work characterizes the effects of opiate (morphine) dependence on auditory brainstem and visual evoked responses in a rhesus macaque model of neuro-AIDS utilizing a chronic continuous drug delivery paradigm. The goal of this study was to clarify whether morphine is protective, or if it exacerbates simian immunodeficiency virus (SIV)-related systemic and neurological disease. Our model employs a macrophage tropic CD4/CCR5 coreceptor virus, SIV mac 239 (R71/E17), which crosses the blood-brain barrier shortly after inoculation and closely mimics the natural disease course of human immunodeficiency virus infection. The cohort was divided into three groups: morphine only, SIV only, and SIV + morphine. Evoked potential (EP) abnormalities in subclinically infected macaques were evident as early as 8 weeks postinoculation. Prolongations in EP latencies were observed in SIV-infected macaques across all modalities. Animals with the highest cerebrospinal fluid viral loads and clinical disease showed more abnormalities than those with subclinical disease, confirming our previous work (Raymond et al.,
Introduction
It has been established that HIV can infect the central nervous system and lead to HIV-1-associated motor/ cognitive disorder and AIDS dementia complex, but the causes of these deficits are poorly understood (Bacellar et al. 1994; Ciardi et al. 1990; Diesing et al. 2002; Everall et al. 1993; Glass et al. 1993; Kanzer 1990; Lipton and1999; Petito et al. 1986; Price et al. 1988) . Combined HIV infection and opiate dependence is a common problem, with estimates that drug abuse may be the second leading method of HIV transmission in the USA (Gayle 2000) . Thus, the interaction of the two leads to questions concerning the effects of drugs of abuse on disease severity and rate of progression (Ansari 2004; Donahoe 2004; Kapadia et al. 2005) . Morphine has been found to influence both innate and adaptive immunity (Roy and Loh 1996; Sharp et al. 1998 ) via opioid receptors on immune cells (McCarthy et al. 2001) . Electrophysiological studies investigating the influence of morphine on HIV-related neuropathology are limited; however, a feline model utilizing both multiple acute and escalating dose (followed by withdrawal) drug delivery paradigms suggests a protective role of morphine on feline immunodeficiency virus (FIV)-related auditory brainstem response (ABR) abnormalities (Barr et al. 2000 (Barr et al. , 2003 . In vitro and in vivo studies of the effects of opiates on AIDS severity and rate of progression have been disparate (Chuang et al. 1993; Donahoe et al. 1993; Donahoe 2004; Kumar et al. 2006; Marcario et al. 2008; Suzuki et al. 2002) . The results of various epidemiological studies vary with some showing that opiates may have a protective role (Spijkerman et al. 1995; Spijkerman et al. 1996a ), others showing a deleterious role (Bouwman et al. 1998; Hutchinson et al. 1997; Krol et al. 1999) , and still others finding no effect (Pezzotti et al. 1999; Prins and Veugelers 1997; Thorpe et al. 2004 ) on HIV-related pathology and/or mortality rates. Unfortunately, human studies are often confounded by differences in drug abuse pattern and duration, polydrug use, as well as widespread implementation of antiviral therapies (Everall 2004; Kapadia et al. 2005) . However, a recent study by Thorpe et al. (2004) , based on a large population of HIV-infected women who were either "hard-drug" users or not, is significant in that it was possible to achieve better control of multiple variables. The authors concluded that "hard-drug" use had no effect on CD4 cell percentage or HIV RNA level in support of most prior epidemiological evidence. Recently, we also reported that morphine had no significant effect on viremia, cerebrospinal fluid (CSF) viral titers, or survival in simian immunodeficiency virus (SIV)-infected macaques over the time course of the study (Marcario et al. 2008 ). However, morphine was associated with a tendency for greater buildup of virus in the brains of infected animals.
Simian immunodeficiency viruses provide excellent models for studying HIV-related neuropathology over a compressed disease time course. The bone marrow passaged macrophage tropic CD4/CCR5 coreceptor virus, SIV mac 239 (R71/E17), used in this study is biologically similar to the HIV phenotype (R5 HIV) which commonly infects patients since both utilize the CCR5 receptor (R5 virus) for entry into macrophages (Alkhatib et al. 1996; Chen et al. 1997; Deng et al. 1996; Dragic et al. 1996; Kirchhoff et al. 1997; Marcario et al. 2008; Marx and Chen 1998) . The SIV mac 239 (R71/E17) virus has been shown to cross the blood-brain barrier shortly after inoculation (Sharma et al. 1992; Narayan et al. 1997 ) and productively replicates primarily in memory CD4+ T cells in the gutassociated lymphoid tissue and spleen (Veazey et al. 1998 (Veazey et al. , 2000a . Our neuropathological and stereological studies, utilizing a cohort of SIV mac R71/17E inoculated Indian origin rhesus macaques, have demonstrated many of the features of HIV-1 encephalopathy Marcario et al. 2004 ) as well as a significant loss of neurons in the lateral geniculate nucleus , the globus pallidus, and the substantia nigra (Marcario et al. 2004) . Thus, our model not only closely mimics the natural disease course of HIV infection but also demonstrates many of the hallmarks associated with HIV-related neurological disease.
SIV-infected animals exhibit altered functional integrity of motor and sensory pathways as well as impaired behavioral performance with the progression of disease (Gold et al. 1998; Horn et al. 1998; Marcario et al. 1999a, b; Murray et al. 1992; Prospero-Garcia et al. 1996; Raymond et al. 1998; Raymond et al. 1999 Raymond et al. , 2000 Weed et al. 2004) . In previous studies using a cohort of SIV mac R71/17E inoculated rhesus macaques, we demonstrated that ABR and visual evoked potential (VEP) peak latency shifts generally correlate with underlying neuropathology at the level of the auditory brainstem nuclei and visual pathway structures . ABR studies, utilizing SIVinfected monkeys and HIV-positive patients, suggest greater dysfunction in rostral regions of the auditory brainstem pathway with disease progression (Castello et al. 1998; Hausler et al. 1991; Horn et al. 1998; Pagano et al. 1992; Prospero-Garcia et al. 1996; Raymond et al. 1998) . VEP abnormalities have been found to be related to retinopathy, optic nerve axonal pathology, and retrochiasmic pathway and primary visual cortex dysfunction (Mahadevan et al. 2006) . ABR and VEP abnormalities in HIV-positive patients are well documented and provide a valuable tool in the assessment of peripheral and central nervous system (CNS) dysfunction in both symptomatic and asymptomatic seropositive patients (Castello et al. 1998; Farnarier and SommaMauvais 1990; Iragui et al. 1996; Koralnik et al. 1990; Mahadevan et al. 2006; Malessa et al. 1995; Mwanza et al. 2004; Pierelli et al. 1993) . Hence, electrophysiological monitoring provides an excellent indicator of early and late central and peripheral functional abnormalities and represents an effective method for assessing the influence of drugs of abuse on physiological integrity.
The goal of the present study was to characterize the electrophysiological consequences of SIV infection combined with opiate (morphine) dependence in a nonhuman primate model of neuro-AIDS.
Material and methods

Subjects
Our cohort consisted of 16, 6-to 7-year-old, male Indian origin rhesus macaques (Macaca mulatta) which were SIV and herpes B virus negative. Animals were individually caged and housed in an Association for Assessment and Accreditation of Laboratory Animal Care-accredited facility which was maintained at 25.0°C. Random assignment was employed to divide the cohort into three groups: morphine only (group M, n=5), SIV only (group V, n=5), and SIV + morphine (group VM, n = 6). ABRs and VEPs were recorded during the control (35 weeks), morphine dependency (26 weeks), and postinoculation period (33 weeks). Based on the type of disease progression, animals were classified as clinical (animals that had to be euthanized before the end of the study due to the presence of serious clinical symptoms, n=4) or subclinical (animals that were terminated at the end of the study and lacked serious clinical symptoms, n=7). Table 1 summarizes the experimental groups (M, V, VM), periods (control, morphine dependency, postinoculation), and procedures. All experimental procedures were in compliance with those outlined in the Guide for the Care and Use of Laboratory Animals.
Drug delivery paradigm
This study utilized a continuous chronic (59 weeks) model of morphine dependence. Initially, animals were acclimated to the intramuscular (i.m.) hindlimb injection protocol by first giving sterile saline injections. All animals were behaviorally trained and tested in another part of the protocol. To minimize interference with behavioral performance, the morphine dosage was gradually increased from 1 mg/kg/injection in week1 to 2.5 mg/kg/injection in week 17. Following the gradual ramp-up, the 2.5-mg/kg/injection dose was maintained for the duration of the experiment. Sham saline injections of equivalent volume were given to group V subjects. All animals were injected every 6 h (6:00 AM, 12:00 PM, 6:00 PM, and 12 AM), 7 days a week. The total final daily dose was 10 mg/kg. To minimize tissue damage and reduce the potential for infection, injections were alternated between the two legs and hair at the site of injection was regularly shaved.
Viral inoculation
Animals in group VM (SIV + morphine) and group V (SIV only) were inoculated via femoral bone marrow injection with neurovirulent SIV mac (R71/17E) provided by Dr. O. Narayan. Each animal in group VM and group V received 0.5 ml of each viral homogenate (R71 and 17E) for a total volume of 1 ml that contained approximately 1,000 TCID 50 . Animals in group M were sham inoculated via femoral bone marrow saline injection.
Electrophysiological testing procedures
Following an initial injection of atropine (0.04 mg/kg i.m.) and ketamine (10 mg/kg i.m.), anesthesia was maintained with subsequent doses of ketamine at 20-30-min intervals.
We have confirmed what others have reported that the latency of EPs does not vary with the depth of ketamine anesthesia in the dose range we used (Ghaly et al. 1990 (Ghaly et al. , 2001 Fig. 1 .
Visual evoked potentials
VEPs were recorded using Grass™ AC amplifiers (Model P511 and HIP5 high impedance preamplifiers) with low and high filter settings of 1 and 100 Hz, respectively, and a gain of 50 k. A Grass™ photic stimulator (Model PS33;
West Warwick, RI, USA) with an illumination intensity setting of 16 was placed 45 cm from the animal's head. The animal's eyelids were retracted to achieve full exposure to the pupils. The stimulator generated binocular flash stimuli at a frequency of 2 Hz. A total of 200 stimulus repetitions were averaged and measured utilizing Windows based Neural Averager software (Larry Shupe, Seattle, WA, USA). VEPs were recorded with the active (+) electrodes placed at O1 and O2 overlying the left and right occipital cortices, respectively. Throughout the text, (O1) and (O2) are used to indicate the source of the signal. Placement was approximately 12 mm rostral to the inion and 12 mm lateral to the midline. Reference electrodes (−) were placed at the right mastoid (M2) and left mastoid (M1). A schematic of the VEP electrode montage is provided in Fig. 1 .
Statistical analysis
ABR and VEP parameters were assessed longitudinally for differences related to group (VM, V, and M) and disease progression type (clinical (C), subclinical (S)). In order to assess the equivalence of the three groups (VM, V, and M) prior to initiation of the morphine protocol, we compared the groups based on the final observation taken during the control period using an omnibus analysis of variance F test for each dependent variable. The control period was used as a covariate in order to correct for pretreatment differences between the groups. Relevant p values were calculated using SAS. A type I error rate of 5% was used to determine statistical significance. Table 1 summarizes the experimental groups and periods.
To assess the effect of morphine on SIV-related evoked potential peak latency shifts, we estimated the time slope (i.e., average change in dependent measure per week) for all three groups (V, M, and VM) during the postinoculation period. This was accomplished using a mixed model for each dependent variable that included time (in weeks), group, and time-by-group interaction as predictors, with the last observation from the morphine dependency period included as a covariate. The model was fit with a first-order autoregressive structure to account for dependencies among the repeated (within-subject) observations. Using the slope estimates generated by this model, we used contrasts to conduct pairwise comparisons between the M and VM groups, V and VM groups, and V and M groups.
To compare disease progression type (C, S) means during the postinoculation period, mixed models including disease progression type (C, S), time (in weeks), and timeby-disease progression type interactions with first-order autoregressive covariance structure were fitted to the ABR and VEP data. The last observation from the morphine dependency period was included as a covariate.
For each dependent variable, we also computed least squares mean estimates of the final and maximum observations for the three groups (V, M, and VM) during the postinoculation period using a general linear model with group as a predictor. The last observation from the morphine dependency period was included as a covariate. We then used contrasts to conduct pairwise comparisons (VM vs. V, VM vs. M, and V vs. M) of these mean estimates. Similarly, for each dependent variable, we also computed least squares mean estimates of the final and maximum observations for the disease progression type (C, S) during the postinoculation period using a general linear model with disease progression type as a predictor. The last observation from the morphine dependency period was included as a covariate.
In addition to group analysis, we conducted single subject analysis using each monkey as its own control. Deviations in measured latencies that exceeded 2 standard deviations (SDs) of the mean during the control period were considered significant . To obtain a better estimate of the variability, the standard deviation was calculated from the data of all monkeys in a particular group but comparisons were with each monkey's own control period mean. For the single subject analysis, imputations were performed on absent values. Absent values resulted from instances when EPs were absent (undetectable) due to disease severity. For the imputed analyses, the maximum value for a specific dependent variable across all animals was substituted for absent values.
Results
Disease profile and onset of conduction delays in relation to disease progression Based on disease profile, macaques were classified as either clinical (animals that had to be euthanized before the end of the study due to disabling clinical symptoms) or subclinical (animals that lacked disabling clinical symptoms and were terminated at the end of the study). Table 2 summarizes the time course of the onset of EP abnormalities in individual monkeys, defined as latencies exceeding two standard deviations of the control period mean. Four of 11 inoculated monkeys (98D264, 98C065, 98C001, 98C089) developed clinical disease (two macaques in each of the VM and V groups; Table 2 ). Clinical signs were evident as early as 13 weeks postinoculation. Seven of 11 inoculated monkeys exhibited subclinical disease and were euthanized at a predetermined date (30 and 31 weeks postinoculation). There were no statistically significant differences in general survival rate, viremia, or CSF viral load between the VM and V groups over the time course of the study (Table 2 ; Marcario et al. 2008 ).
ABR latency changes
The present study demonstrates that significant postinoculation increases occurred in ABR parameters confirming our earlier work . Figure 2 provides representative examples of serial ABRs recorded at similar time points during the control and morphine dependency periods. The final recording was just prior to necropsy. As observed in human ABR recordings, within monkey ABR waveform morphology and peak latencies are highly stable and reproducible over time, although there is significant across animal variability. As shown in the examples of Fig. 2 , significant peak latency and interpeak interval (IPI) shifts did not occur during the morphine dependency period. Of particular interest are the postinoculation latency shifts in ABR peaks II and IV in macaque 98C089 (group V) and peaks III, IV, and V in macaque 98C065 (group VM). Both of these animals had clinical disease. Prolongations in peak latencies have been related to delays in conduction velocity associated with demyelination.
The results of the current study confirm that ABR testing can be a valuable tool in assessing the influence of drugs of abuse on physiological integrity. Table 2 shows that ABR abnormalities occurred prior to the onset of clinical symptoms in three animals with clinical disease [98D264 (group VM), 98C065 (group VM), 98C089 (group V)] and two animals with subclinical disease [98C095 (group VM), 98D321 (group V)]. A total of four animals with subclinical disease exhibited ABR abnormalities, further emphasizing the value of evoked potential studies for the early detection of functional abnormalities. Increases in peak latency in the subclinical animals typically corresponded with peaks in CSF and/or plasma viral loads. Our findings indicate that animals with clinical disease showed ABR abnormalities as early as 12 weeks postinoculation. Although the onset of ABR abnormalities varied between animals, at end stage, most of the animals with clinical disease exhibited increases greater than two standard deviations above the control mean in at least one ABR parameter (Table 2) . It is worth noting that three macaques with subclinical infections did not show statistically significant increases in ABR latencies throughout the course of the study. Table 3 provides a within-period (morphine dependency, postinoculation) single subject analysis of the number of monkeys which exhibited latencies or IPIs greater than 2 SDs above the control period mean. No ABR abnormalities occurred during the morphine dependency period in macaques in either the VM, V, or M group (Table 3) . Table 3 also shows that the majority of increases in EP Abnormality = latency > 2 SDs of the control period mean for that animal VM SIV + morphine, V SIV only, M morphine only, C clinical (animals that were euthanized before the end of the study due to serious clinical symptoms), S subclinical (animals that were terminated at the end of the study and lacked serious clinical symptoms), NA not applicable, -no impairment, pi postinoculation, pm morphine (Table 3) suggest greater abnormalities in the VM macaques compared to V macaques, our group analyses revealed no statistically significant group differences between VM and V, VM and M, and V and M. However, statistically significant group differences did occur between the clinical and subclinical macaques. Specifically, animals with clinical disease showed greater ABR abnormalities in peak III (p=0.0110) than animals with subclinical disease confirming our previous findings ).
VEP latency changes
As shown in Table 2 , VEP abnormalities occurred 4-9 weeks earlier than the onset of clinical symptoms in three out of four animals with clinical disease [98D264 (group VM), 98C001 (group V), 98C089 (group V)]. In fact, one animal with clinical disease (98C089) showed VEP abnormalities as early as 4 weeks postinoculation. While the onset of VEP abnormalities varied between animals, at end stage, all of the animals with clinical disease exhibited increases greater than 2 SDs above the control mean in at least one VEP parameter (Table 2) . Our flash-evoked VEPs were less reproducible than the ABRs. Nevertheless, it was clear that some end-stage VEP deficits were more severe than ABR abnormalities. This is illustrated in Fig. 2 which shows the complete loss of the VEP associated with end-stage disease (98C089, group V, animal with clinical disease). This observation is consistent with our previous study in which two rapid progressors exhibited undetectable VEP peaks at end-stage disease . Note also the significant end-stage increase in the N1 peak in macaque 98C065 (group VM, animal with clinical disease). No significant change in VEP parameters was evident in the morphine-only animal illustrated in Fig. 2 (macaque 98C042) . Table 3 provides single subject within-period (morphine dependency, postinoculation) analysis of the number of animals which exhibited latency increases greater than 2 SDs above the control period mean. None of the animals in any group exhibited latencies greater than 2 SDs during the morphine dependency period (preinoculation). During the postinoculation period, 11 VEP abnormalities were found in the V group compared to seven in the VM group. No abnormalities were found in the M group of animals during the postinoculation period.
Our group analysis revealed significant findings (Table 4) . First, VM macaques showed greater abnormalities in P1 (O1) (p=0.0383) compared to V group animals. Our group analyses also showed significant group abnormalities in VM macaques compared to M macaques for the following 
ABR condensation polarity (M1 and M2, see 
Discussion
We assessed the influence of well-maintained chronic (59 weeks) morphine dependence (2.5 mg/kg i.m., every 6 h, 7 days a week) on ABRs and VEPs in a cohort of 16 Indian origin rhesus macaques which were divided into three groups: (1) morphine only (M), (2) SIV only (V), and (3) SIV + morphine (VM). Prolongations in ABR and VEP latencies were observed in SIV-infected animals with and without morphine dependence confirming our previous work . Although more ABR abnormalities were found in group VM than group V (17 vs seven; Table 3 ), it is important to note that a similar fraction of monkeys in each group had abnormalities (4/6 for VM vs 3/5 for V; Table 2 ), and hence, it is difficult to conclude that morphine significantly increased incidence compared to virus alone. The data on VEPs showed more abnormalities in the V group than the VM group (11 vs seven; Table 3 ) and also a greater fraction of monkeys in the V group had abnormalities than in the VM group (4/5 for V vs 3/6 for VM; Table 2 ), although the numbers are small. Also, the animal that showed complete loss of the VEPs was in the V group (Fig. 2) . These results might actually be used to argue in favor of a protective effect of morphine but a conservative interpretation would be that morphine clearly did not increase the number of SIVinfected animals with VEP abnormalities of the time period of this study. Our group statistical analysis failed to reveal many significant differences. Nevertheless, one noteworthy significant difference was observed. Peak P1 (O1) of the visual evoked potential in the VM group showed a greater increase in latency than the V group. Differences were found between the VM and M groups but, surprisingly, none were found between the V and M groups. A major limitation impeding our group analysis was the relatively small number of monkeys in each group in relation to effect magnitude.
Macaques in both the VM and V groups exhibited greater dysfunction in later peaks of the ABR suggesting dysfunction at the level of the superior olivary nucleus (hypothesized generator of peak III and possibly peak IV), lateral lemniscus tracts and nuclei (hypothesized generator of peak IV and possibly peak V), and/or inferior colliculus (hypothesized generator of peak V) (Buchwald and Huang 1975; Curio and Oppel 1988; Hashimoto 1982; Hashimoto et al. 1981; Legatt et al. 1986; Moller and Burgess 1986; Moller and Jannetta 1982a, b; Moller et al. 1981a Moller et al. , b, 1994 . VEP abnormalities, in some cases including complete loss of the VEP (macaque 98C089), could result from pathophysiology anywhere along the visual pathway. The occipital cortex is the most likely generator for the VEP (Kraut et al. 1985) , but loss or slowing of the flash-evoked visual volley at any point along the pathway would affect the potential generated at the cortex.
In agreement with our previous findings , the time course of the development of overt clinical disease (i.e., clinical vs subclinical animals) was an excellent indicator of severity of neural pathology and CSF viral load. Animals which developed clinical disease (four out of 11 inoculated animals; two animals in each of the VM and V groups) consistently exhibited (1) more severe sensory electrophysiological abnormalities and (2) elevated CSF viral RNA copies. In previous work on this same cohort of monkeys, we showed that clinical disease was also associated with higher viral concentrations in the basal ganglia, occipital cortex, parietal cortex, deep white matter, and brainstem (Marcario et al. 2008) . 
Group differences were assessed utilizing the least squares means of the maximum latencies during the postinoculation period; the morphine dependency period was used as a covariate VM SIV + morphine, V SIV only, M morphine only, C clinical (animals that had to be euthanized before the end of the study), S subclinical (animals that were terminated at the end of the study); -no significant group difference (p<0.05) a No statistically significant group differences occurred for any of the ABR peak latencies and interpeak intervals between VM and V, VM and M, and V and M Disease profile Four of 11 inoculated monkeys (98D264, 98C065, 98C001, 98C089) developed clinical disease (two macaques in each of the VM and V groups; Table 2 ). It should be noted that some animals in the morphine only group also developed clinical signs. Mild tremor was present in two animals (macaques 98C067 and 98C097; Table 2 ). Tremor has been associated with opioid withdrawal in both humans and nonhuman primates (Seevers 1936) . Given the fact that our animals were injected with morphine every 6 h and did not exhibit signs of withdrawal (i.e., dysphoria, gastrointestinal problems), it is unlikely that the observed tremor was related to fluctuations in plasma opioid levels. Lalley et al. (1975) observed that intracaudate injection of morphine in unanesthetized cats produced resting tremor thought to be associated with reduced dopamine function and it is possible that the mild tremor we observed in some monkeys may have had a similar origin. Necrotizing myositis/dermatitis was present at the site of morphine injection in two of five animals (macaques 98C070 and 98C110) in the morphine only group. It is noteworthy that cutaneous complications associated with injection drug use are well documented and include cutaneous infections (Beaufoy 1993; Binswanger et al. 2000; Spijkerman et al. 1996b ), necrotizing fasciitis (Callahan et al. 1998; Chen et al. 2001 ) and necrotizing ulcers (Bruckner et al. 1982; Scott et al. 1997) . The possibility of local immune suppression at the site of morphine injections can be raised although it would seem that the VM group monkeys would also be affected. However, the numbers of monkeys in our groups might be too small to draw conclusions. A synergistic effect between cocaine and cutaneous streptococcal infection has been suggested by Hoeger et al. (1996) . However, the direct cytotoxic effects of opiates must also be considered (Bruckner et al. 1982; Scott et al. 1997 ).
Virological, immunological, and neuropathological correlations
Clinical disease was associated with high CSF viral RNA copies and more severe EP abnormalities. For example, once viral loads exceeded 10 7 to 10 8 copies of viral RNA/ml CSF, all macaques with clinical disease showed prolongations in at least one VEP parameter and three out of four macaques with clinical disease (macaques 98D264, 98C065, 98C089) had increases in at least one ABR parameter. Although CSF viral loads were a good indicator of EP abnormalities, it should be noted that in macaque 98C095 (group VM, subclinical), increases in ABR peaks III-V and I-III IPIs, III-V IPIs, and I-V IPIs as well as VEP P1 (O1) and P1 (O2) corresponded with plasma viral loads exceeding 10 7 copies of viral RNA/ml plasma while CSF viral loads remained relatively low.
Viral RNA was recovered from plasma and CSF samples of all inoculated macaques (n=11) indicating productive infection. There was no statistically significant difference in CSF (Wilcoxon-Mann-Whitney test, p=0.095 to 0.792) and plasma (Wilcoxon-Mann-Whitney test, p=0.43 to 0.99) viral RNA copies between the V and VM groups at the examined time points throughout the duration of the study (Marcario et al. 2008 ). However, there was a statistically significant difference in CSF viral RNA copies between macaques with clinical disease vs. those with subclinical infections (Wilcoxon-MannWhitney test, p=0.006, clinical>subclinical) for the average of the final two measurement weeks prior to necropsy. Plasma viral RNA copies were significantly higher in macaques with clinical disease compared to those with subclinical infections (Wilcoxon-Mann-Whitney test, p=0.006 to 0.042) at all examined time points except the average of 3-4 weeks p.i. (p=0.073) and the average of the final two measurement weeks prior to necropsy (Marcario et al. 2008) .
Following inoculation, peripheral blood mononuclear cells from macaques in the V and VM groups were examined for development of cell-mediated immunity responses to the virus. We found a morphine-associated loss of enzyme-linked immunosorbent spot (ELISPOT) responses (Marcario et al. 2008) . Specifically, all animals in the V group developed ELISPOT responses; however, none of the animals in the VM group developed any ELISPOT responses during any of the sampling periods. Although there was no statistically significant difference in CSF and plasma viral RNA copies between the V and VM groups, the results suggest that morphine could have a gradual influence on SIV-related pathogenesis. In addition, although there were no statistically significant differences in SIV gag levels between the V and VM groups for the tested peripheral tissues or brain regions, higher tissue viral concentrations were found in subclinical VM animals compared to subclinical V animals, as 15 of 16 tissue samples in the VM group compared to four of 12 tissue samples in the V group exceeded 10 6 copies of viral RNA. In addition, subclinical animals in the VM group exhibited a trend toward higher viral titers in the brain (14 of 20 brain regions had viral titers exceeding 10 4 copies of viral RNA) than subclinical animals in the V group (four of 15 brain regions had viral titers exceeding 10 4 copies of viral RNA). These data, coupled with the morphine associated suppression of cell-mediated immune responses (i.e., loss of ELISPOT responses), suggest that, with time, macaques in the VM group with subclinical infections might have eventually progressed more rapidly to clinical AIDS than animals in the V group animals.
The macaques with clinical disease (four out of 11 inoculated animals) exhibited the most severe neuropathological and EP abnormalities. Lentivirus-induced neuropathology included multinucleate giant cell reactions, perivascular mononuclear infiltrates, meningoencephalitis, microglial nodule formation, and radiculoneuritis. Macaques with subclinical disease (seven out of 11 inoculated animals) did not exhibit the hallmarks of AIDS-related neuropathology. However, it should be noted that although not a classical lentiviral encephalitis, macaque 98D388 (group V, subclinical) showed a minimal single site perivascular cuff. In addition, macaque 98C088 (group VM, subclinical) exhibited mild meningitis, specifically the meninges contained a focal site of lymphoid inflammation. Although there were no obvious pathological findings in most of the macaques in the M group, there was a focal site glial nodule composed of macrophages/microglia within the basal ganglia, proximate to the internal capsule in macaque 98C097 (group M).
In a previous study utilizing a cohort of SIV mac R71/17E inoculated macaques, we found inflammatory pathology in animals with clinical disease in the optic nerves and tracts, lateral geniculate bodies, superior colliculi, and calcarine cortices . Additional pathology included areas of spongiform vacuolation, neuronal loss, and a reactive gliosis in cortical layers III and IV of the visual cortex . We also showed mild to severe degrees of lentivirus-induced auditory pathway pathology found in the cochlear nucleus, lateral lemniscus, olivary complex, inferior colliculus, and medial geniculate body . Although exceptions exist, our previous work suggests that the degree of lentivirusinduced neuropathology generally correlates with the severity of EP abnormalities . Similar pathology can be assumed to have contributed to the increases in ABR peaks III-V and I-III IPIs, III-V IPIs, I-V IPIs, as well as VEP N1 and P1 latencies observed in the present study.
Comparison to previous studies of evoked potentials
The influence of chronic (59 weeks) morphine dependence on SIV-related auditory neuropathology has to our knowledge never been addressed in primates prior to this study. Studies utilizing a feline model which employed both multiple acute and escalating dose (followed by withdrawal) drug delivery paradigms suggest a protective role of morphine on FIVrelated ABR abnormalities (Barr et al. 2000 (Barr et al. , 2003 . Specifically, Barr et al. (2003) , using an escalating dose of morphine (1.0-2.0 mg/kg/day) followed by withdrawal, found that although significant postinoculation ABR peak 4 latency increases occurred in FIV-infected animals without morphine (V group), there was no significant difference in peak 4 latencies between control animals (saline-treated, uninfected animals) and morphine-treated, FIV-infected animals (VM group). Similarly, in a cat study of multiple acute morphine exposures (1 injection of 2.0 mg/kg/day for two consecutive days/week), Barr et al. (2000) found that significant postinoculation increases in ABR peak 4 did not occur in morphine-treated FIV-infected animals (VM group) in contrast to FIV-only animals (V group) which developed significant peak 4 increases after 16 weeks postinoculation.
The above findings are in accord with previous studies utilizing a simian model of chronic (i.e., low-stress) morphine dependence which reported a protective role (lower viral loads, slower disease progression, although no neurophysiological studies) of morphine on SIV-related disease progression (Donahoe et al. 1993; Donahoe 2004) . The nature of the observed neuroprotective influence of morphine could be related to a reduction in elevated excitotoxic extracellular glutamate levels associated with lentivirus (Barr et al. 2000; Lipton 1998; Manzoni and Williams 1999; Sepulveda et al. 1998; Thorlin et al. 1998) . Although the exact immunoprotective mechanisms of morphine are unknown, the aforementioned studies suggest that morphine dosage as well as the drug delivery paradigm, for example, length of exposure, may influence disease outcome (Barr et al. 2000; Donahoe 2004; Kapadia et al. 2005 ).
Possible role of viral strain and morphine drug regimen in simian studies
The SIV model provides an excellent paradigm for studying HIV-related pathogenesis. Previous studies have reported enhanced SIV and/or SHIV replication in morphine-treated macaques (Chuang et al. 1993; Kumar et al. 2006) . Specifically, Kumar et al. (2006) inoculated macaques with a combination of SHIV KU , SHIV 89.6 P, and SIV/17E-Fr and reported that morphine-treated and virus-infected animals exhibited (1) higher CSF and plasma viral loads, (2) more rapid blood-brain barrier viral migration with SHIV KU , and (3) more rapid disease onset. Simian studies suggesting a protective role of morphine-inoculated animals with SIV smm9 and used relatively high doses of morphine (Donahoe et al. 1993; Donahoe 2004) . Incongruent findings regarding morphine's possible effects may be due in part to differences in viral strain resulting in different CD4 profiles and severity of neurovirulence. Specifically, SIV smm9 may not be as virulent as viruses used in other studies (Fultz et al. 1986; Suzuki et al. 2002) . Morphine dose may also be a factor, although the dosages used in all the monkey studies, including this one, are sufficient to produce clear dependence.
Comparison with epidemiological studies
Epidemiological studies of opiate dependence on HIV disease progression in humans have yielded inconsistent results. Several reports suggest higher rates of HIV encephalitis and microglial activation in heroin addicts (Bell et al. 1998; Davies et al. 1997; Tomlinson et al. 1999) as well as an increased incidence of opportunistic infections in "hard-drug" users (Thorpe et al. 2004) . In an effort to dissect the role of HIV infection and drugs of abuse on neuropathology, Bell et al. (2002) compared microglial activation and other parameters in drug users with HIV encephalitis (HIVE), HIV-negative drug users, and controls without HIV or drug use. Most noteworthy was the fact that not only did the HIVE drug-using group show increased microglial activation compared to controls but so did the HIV-negative drug users. An interaction between these separate effects on microglial activation might provide a mechanism for potentiation of disease in drug users. A later study (Arrango et al. 2004) comparing HIVE drug users with HIVE nondrug users revealed a trend in the thalamus toward greater microglial activation in the drug users, although this difference did not achieve statistical significance. Multidrug use characterized the subjects in these studies though most were opiate users. Both lower and higher mortality rates associated with combined HIV infection and drug use have been reported (Alcabes and Friedland 1995; Selwyn et al. 1992) . However, the majority of epidemiological studies report that opiate use has neither a protective nor a deleterious role in HIV-related disease (Pezzotti et al. 1999; Prins and Veugelers 1997; Thorpe et al. 2004) . The study by Thorpe et al. (2004) is particularly significant in that it was based on a large population of HIV-infected women some of whom were hard drug users (including heroin/opiates) that could be compared with a group of nondrug users. Not only were the drug and nondrug groups more comparable than is often the case in epidemiological studies of men, but it was also possible in this study to confirm self reports of drug use with blood samples. The authors conclude that "In this large cohort of HIV-infected women, we found no effect of hard drugs on virological or immunological markers of HIV disease progression, nor did hard-drug using women progress more rapidly to death than nonusers. However, a greater number of hard-drug-using women did develop class C events (AIDS defining, e.g., pneumonia) than non-users, both before enrollment and during the study period." Overall, our results on ABR and visual evoked potentials provide evidence consistent with these conclusions. However, an important caveat must be raised. Morphine treatment was associated with a tendency for greater build-up of virus in the brains of infected animals suggesting that if we were able to follow these animals for a longer period of time, a clearer picture of morphine-related evoked potential abnormalities might have emerged (Marcario et al. 2008) .
Conclusions
Increases in EP latencies were observed in SIV-infected macaques across all modalities. Animals with the highest CSF viral loads and clinical disease showed more abnormalities than those with subclinical disease, confirming our previous work . Our evoked potential analysis of morphine's effects on SIV disease severity and progression yielded mixed results. More ABR abnormalities were observed in the VM compared to the V group (17 vs seven). In contrast, the fraction of animals with ABR abnormalities was similar for both the VM and V groups (4/6 for VM vs 3/5 for V) and the number of animals with VEP abnormalities was either not different or slightly higher for the V group compared to the VM group (11 vs seven). The fraction of animals with VEP abnormalities was also similar given the small sample size (4/5 for V vs 3/6 for VM). Overall, while some differences were observed, they were relatively small and not consistent across evoked potential type. However, we must qualify this by stating that the morphine-treated animals did show complete inhibition of ELISPOT responses against the virus and VM animals with subclinical disease also had a tendency toward higher viral titers in peripheral and CNS tissues than untreated animals (Marcario et al. 2008) . It is possible that if all animals had been followed to end-stage disease, a clearer pattern of greater evoked potential dysfunction in the VM group compared to the V group might have emerged.
